Lv11
40 积分 2023-11-28 加入
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
2小时前
已完结
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
2天前
已完结
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
22天前
已完结
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia
23天前
已完结
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
23天前
已完结
Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma
1个月前
已完结
The Financial Burden of Localized and Metastatic Bladder Cancer
1个月前
已完结
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
1个月前
已完结
Progression-free survival is an adequate endpoint for clinical trials of locally advanced and metastatic urothelial carcinoma
1个月前
已关闭
Assessing Treatment Outcomes of Patients Undergoing Enfortumab Vedotin Dose Reduction in Metastatic Bladder Cancer
2个月前
已关闭
皖公网安备34019202002308
